Skip to main content

Advertisement

SpringerLink
Log in

Uveitis in Seronegative Arthritis

  • SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Uveitis is the most frequent extra-articular feature in seronegative arthritis and is part of the classification criteria for spondyloarthritis. Recent studies confirm a prevalence of up to one third of patients with spondyloarthritis and a relationship with HLA-B27 and disease duration. In recent forms of the disease, a relation with infectious episodes, inflammatory bowel disease, and cervical spine involvement has been reported. Many data argue for the implication of the IL23/IL17 pathway in uveitis, already obvious in spondyloarthritis. Studies with NSAIDs, DMARDs, and anti-TNF agents demonstrated the ability of these treatments to reduce the incidence of flares of uveitis in spondyloarthritis. Only a few data are available with other biologic agents. New onset of uveitis during anti-TNF therapy has been reported. The Il-17 blockade may be a new option for treating both uveitis and the underlying rheumatic condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Munoz-Fernandez S, Martin-Mola E. Uveitis. Best Pract Res Clin Rheumatol. 2006;20:487–505.

    Article  PubMed  Google Scholar 

  2. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67:955–9.

    Article  PubMed  CAS  Google Scholar 

  3. Sampaio-Barros PD, Conde RA, Bonfiglioli R, Bértolo MB, Samara AM. Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int. 2006;26:1143–6.

    Article  PubMed  Google Scholar 

  4. Linder R, Hoffmann A, Brunner R. Prevalence of the spondyloarthritidies in patients with uveitis. J Rheumatol. 2004;31:2226–9.

    PubMed  Google Scholar 

  5. Monnet D, Breban M, Hudry C, Dougados M, Brézin AP. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology. 2004;111:802–9.

    Article  PubMed  Google Scholar 

  6. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.

    Article  PubMed  CAS  Google Scholar 

  7. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brand J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31.

    Article  PubMed  CAS  Google Scholar 

  8. Chung YM, Liao HT, Lin KC, Lin YC, Chou CT, Chen CH, Tsai CP. Prevalence of spondyloarthritis in 504 Chinese patients with HLA-B27-associated acute anterior uveitis. Scand J Rheumatol. 2009;38:84–90.

    Article  PubMed  CAS  Google Scholar 

  9. Muñoz-Fernández S, de Miguel E, Cobo-Ibáñez T, Madero R, Ferreira A, Hildago MY, et al. Enthesis inflammation in recurrent acute anterior uveitis without spondylarthritis. Arthritis Rheum. 2009;60:1985–90.

    Article  PubMed  Google Scholar 

  10. Chen CH, Lin KC, Chen HA, Liao HT, Liang TH, Wang HP, Chou CT. Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan. Clin Rheumatol. 2007;26:953–7.

    Article  PubMed  Google Scholar 

  11. • Canouï-Poitrine F, Kemta Lekpa F, Farrenq V, Boissinot V, Hacquardo-Bouder C, Comet, D, et al. Prevalence and factors associated with uveitis in spondyloarthropathies patients in France: Results from the EXTRA observational survey. Arthritis Care Res (Hoboken). 2012 Jan 19. doi:10.1002/acr.21616. A nationwide cross-sectional study of uveitis in spondyloarthritis patients, with confirmation of the high prevalence of uveitis in this condition and its relation with HLA-B27 and disease duration.

  12. Dougados M, d’Agostino MA, Benessiano J, Berenbaum F, Breban M, Claudepierre P, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine. 2011;78:598–603.

    Article  PubMed  Google Scholar 

  13. • Wendling D, Prati C, Demattei C, Miceli C, Daures JP, Dougados M. Impact of uveitis on the phenotype of patients with recent inflammatory back pain. Data from the DESIR cohort. Arthritis Care Res (Hoboken). 2012 Feb 21. doi: 10.1002/acr.21648. First data about uveitis in this prospective cohort of potential early spondyloarthritis, uveitis being associated in this population with recent infectious episode and inflammatory bowel disease.

  14. • Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, et al. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res. 2012;31:182-94. Clear description of the several immunological pathways involved in the development of noninfectious uveitis.

  15. Wakefield D, Chang JH, Amjadi S, Maconochie Z. Abu El-Asrar A, McCluskey P. What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm. 2011;19:139–44.

    Article  PubMed  CAS  Google Scholar 

  16. Chavan H, Samant R, Deshpande A, Mankeshwar R. Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis. 2011;14:369–74.

    Article  PubMed  Google Scholar 

  17. El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, et al. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology. 2006;113:695–700.

    Article  PubMed  Google Scholar 

  18. Pratap DS, Lim LL, Wang JJ, Mackey DA, Kearns LS, Stawell RJ, et al. The role of toll-like receptor variants in acute anterior uveitis. Mol Vis. 2011;17:2970–7.

    PubMed  CAS  Google Scholar 

  19. Levinson RD, Martin TM, Luo L, Ashouri E, Rosenbaum JT, Smith JR, et al. Killer cell immunoglobulin-like receptors in HLA-B27-associated acute anterior uveitis, with and without axial spondyloarthropathy. Invest Ophthalmol Vis Sci. 2010;51:1505–10.

    Article  PubMed  Google Scholar 

  20. Díaz-Peña R, Blanco-Gelaz MA, López-Larrea C. KIR genes and their role in spondyloarthropathies. Adv Exp Med Biol. 2009;649:286–99.

    Article  PubMed  Google Scholar 

  21. Jung KH, Kim TH, Sheen DH, Lim MK, Lee SK, Kim JY, et al. Associations of vitamin d binding protein gene polymorphisms with the development of peripheral arthritis and uveitis in ankylosing spondylitis. J Rheumatol. 2011;38:2224–9.

    Article  PubMed  CAS  Google Scholar 

  22. Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int. 2010;30:1547.

    Article  PubMed  Google Scholar 

  23. Rosenzweig HL, Galster K, Vance EE, Ensign-Lewis J, Nunez G, Davey MP, Rosenbaum JT, et al. NOD2 deficiency results in increased susceptibility to peptidoglycan-induced uveitis in mice. Invest Ophthalmol Vis Sci. 2011;52:4106–12.

    Article  PubMed  CAS  Google Scholar 

  24. Kezic JM, Glant TT, Rosenbaum JT, Rosenzweig HL. Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res Ther. 2012;14(1):R18.

    Article  PubMed  CAS  Google Scholar 

  25. Oh K, Byoun OJ, Ham DI, Kim YS, Lee DS. Invariant NKT cells regulate experimental autoimmune uveitis through inhibition of Th17 differentiation. Eur J Immunol. 2011;41:392–402.

    Article  PubMed  CAS  Google Scholar 

  26. Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010;91:162–70.

    Article  PubMed  CAS  Google Scholar 

  27. Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS One. 2012;7:e29742.

    Article  PubMed  CAS  Google Scholar 

  28. Kezic JM, Davey MP, Glant TT, Rosenbaum JT, Rosenzweig HL. Interferon-γ regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis. Arthritis Rheum. 2012;64:762–71.

    Article  PubMed  CAS  Google Scholar 

  29. Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann Rheum Dis. 2012 Jan 20. [Epub ahead of print]

  30. Onal S, Kazokoglu H, Incili B, Demiralp EE, Yavuz S. Prevalence and levels of serum antibodies to gram negative microorganisms in Turkish patients with HLA-B27 positive acute anterior uveitis and controls. Ocul Immunol Inflamm. 2006;14:293–9.

    Article  PubMed  CAS  Google Scholar 

  31. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Bonilla G, Ruiz-Sancho D, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30:1277–9.

    PubMed  Google Scholar 

  32. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3A):340–3.

    Article  Google Scholar 

  33. Muñoz-Fernández S, García-Aparicio AM, Hidalgo MV, Platero M, Schlincker A, Bascones ML, et al. Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye (Lond). 2009;23:1130–3.

    Article  Google Scholar 

  34. Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010;18:116–20.

    Article  PubMed  Google Scholar 

  35. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447–51.

    Article  PubMed  CAS  Google Scholar 

  36. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, Dougados M. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631–4.

    Article  PubMed  CAS  Google Scholar 

  37. Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696–701.

    Article  PubMed  CAS  Google Scholar 

  38. • Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, Freundlich B. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010;69:226–9. A systematic analysis of the literature concerning the frequency of uveitis in the clinical trials with etanercept.

    Article  PubMed  CAS  Google Scholar 

  39. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56:3248–52.

    Article  PubMed  CAS  Google Scholar 

  40. • Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41:503–10. A nationwide study of the cases of new onset uveitis in anti TNF treated patients with rheumatologic condition, in comparison with the number of exposed patients for each condition.

    Article  PubMed  Google Scholar 

  41. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50:1390–4.

    Article  CAS  Google Scholar 

  42. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35–9.

    Article  PubMed  CAS  Google Scholar 

  43. Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62:821–5.

    Article  CAS  Google Scholar 

  44. Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382–3.

    Article  PubMed  CAS  Google Scholar 

  45. Wendling D, Dernis E, Prati C, Frisch E, Delbosc B. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011;38:2284.

    Article  PubMed  Google Scholar 

  46. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.

    Article  PubMed  Google Scholar 

  47. Dougados M, Braun J, Vargas RB, Gossec L, Maksymowych W, Sieper J, van der Heijde D. ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis. Ann Rheum Dis. 2012 Jan 30. [Epub ahead of print]

Download references

Disclosure

Dr. Wendling has served on boards for SOBI and Pfizer, has received grant support from Pfizer, Servier, Roche Chugai, and Schering-Plough, has received payment for development of educational presentations (including service on speakers’ bureaus) from Abbott Laboratories, Amgen, Bristol-Myers Squibb, Pfizer, Roche Chugai, and Schering-Plough, and has had travel/accommodations expenses covered/reimbursed by Abbott Laboratories, Amgen, Pfizer, Roche Chugai, and Schering-Plough.

Author information

Authors and Affiliations

  1. Department of Rheumatology, University Teaching Hospital, and University of Franche-Comté, Besançon, France

    Daniel Wendling

  2. Service de Rhumatologie, CHU, Boulevard Fleming, 25030, Besançon, France

    Daniel Wendling

Authors
  1. Daniel Wendling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Wendling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wendling, D. Uveitis in Seronegative Arthritis. Curr Rheumatol Rep 14, 402–408 (2012). https://doi.org/10.1007/s11926-012-0267-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-012-0267-1

Keywords

Search

Navigation